Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Global Blood Therapeutics price target raised to $133 from $122 at Wells Fargo » 09:11
05/07/20
05/07
09:11
05/07/20
09:11
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough raised the firm's price target on Global Blood Therapeutics to $133 from $122 following better than expected Q1 results and strong launch of recently approved OXBRYTA for sickle cell disease. The analyst keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

05/07/20 Oppenheimer
Global Blood Therapeutics price target raised to $101 from $88 at Oppenheimer
05/07/20 Cantor Fitzgerald
Global Blood Therapeutics price target raised to $130 from $105
05/06/20 Piper Sandler
Piper says Global Blood Therapeutics Q1 revenues beat 'homerun scenario'
04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
Hot Stocks
Global Blood Therapeutics announces new employment inducement grants » 09:01
05/07/20
05/07
09:01
05/07/20
09:01
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Global Blood Therapeutics…

Global Blood Therapeutics announced that on May 1, 2020, the compensation committee of GBT's board of directors granted seven new employees restricted stock units for an aggregate of 36,500 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The 2017 Inducement Equity Plan was adopted by GBT's board of directors in January 2017 and has been amended and restated from time to time.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

05/07/20 Oppenheimer
Global Blood Therapeutics price target raised to $101 from $88 at Oppenheimer
05/07/20 Cantor Fitzgerald
Global Blood Therapeutics price target raised to $130 from $105
05/06/20 Piper Sandler
Piper says Global Blood Therapeutics Q1 revenues beat 'homerun scenario'
04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
Recommendations
Global Blood Therapeutics price target raised to $101 from $88 at Oppenheimer » 08:48
05/07/20
05/07
08:48
05/07/20
08:48
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach raised the firm's price target on Global Blood Therapeutics to $101 from $88 and keeps an Outperform rating on the shares. The analyst believes the company's "strong" Q1 results point to substantial demand for Oxbryta, and has revised his revenue projections. Despite the pandemic, Global Blood has made headway with on-boarding payers, and expects to secure broad coverage by the end of 2020, he adds.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

05/07/20 Cantor Fitzgerald
Global Blood Therapeutics price target raised to $130 from $105
05/06/20 Piper Sandler
Piper says Global Blood Therapeutics Q1 revenues beat 'homerun scenario'
04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
Recommendations
Global Blood Therapeutics price target raised to $130 from $105 » 07:20
05/07/20
05/07
07:20
05/07/20
07:20
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Global Blood Therapeutics to $130 from $105 and keeps an Overweight rating on the shares after Q1 sales and early new start trends beat expectations. Although the company is seeing slowing in new starts in Q2, Young believes that it has built a robust foundation of patients, and expects new start trends to resume strong levels after major restrictions related to COVID-19 are lifted. The analyst believes the Oxbryta launch is going better than expected and is now tracking well-above previous consensus of $47M for 2020.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

05/06/20 Piper Sandler
Piper says Global Blood Therapeutics Q1 revenues beat 'homerun scenario'
04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
Recommendations
Piper says Global Blood Therapeutics Q1 revenues beat 'homerun scenario' » 16:43
05/06/20
05/06
16:43
05/06/20
16:43
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Piper Sandler analyst…

Piper Sandler analyst Danielle Brill said Global Blood Therapeutics' Oxbryta revenues of $14.1M beat her $6M estimate as well as her "homerun scenario" bar of $10M. The analyst, who said its other metrics also look good and believes the results point to strong underlying demand, would expect the stock to be up tomorrow. She maintains an Overweight rating on the stock ahead of the company's earnings call.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
03/18/20 Cowen
Global Blood Therapeutics Oxbryta launch slowed, says Cowen
Hot Stocks
Global Blood says paused new patient screening and enrollment due to pandemic » 16:39
05/06/20
05/06
16:39
05/06/20
16:39
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Global Blood Therapeutics…

Global Blood Therapeutics said that it has paused new patient screening and enrollment in company-sponsored clinical trials due to the COVID-19 pandemic, while continuing to support patients already enrolled in studies and conduct study-related administrative activities. "GBT anticipates restarting enrollment in these clinical trials at an appropriate time and currently does not expect this pause to impact long-term timelines for its clinical trials, including the completion of the HOPE-KIDS 2 post-approval confirmatory study," the company stated in its quarterly report.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
03/18/20 Cowen
Global Blood Therapeutics Oxbryta launch slowed, says Cowen
Earnings
Global Blood Therapeutics reports Q1 EPS ($1.20), consensus ($1.51) » 16:38
05/06/20
05/06
16:38
05/06/20
16:38
GBT

Global Blood Therapeutics

$81.88 /

+2.67 (+3.37%)

Reports Q1 revenue…

Reports Q1 revenue $14.1M, consensus $3.66M. "Our first quarter performance exceeded our expectations and demonstrates the quality of execution across our entire organization as well as our employees' commitment to deliver Oxbryta, a first-in-class therapy that directly inhibits the sickling and destruction of red blood cells. We have received positive feedback from patients and physicians, with increased awareness of Oxbryta and many patients responding well. We are pleased that a growing number of sickle cell disease patients have started Oxbryta therapy and are enrolling in GBT Source, our patient support program. Our payer education activities are also going well, and we believe we are on track to meet our goal of obtaining broad payer coverage by the end of the year," said Ted Love, president and CEO of GBT. Reports approximately 1,650 new patient prescriptions of Oxbryta during the first quarter, for a total of approximately 2,000 since launch. "The vast majority of new patient prescriptions were enrollments into GBT Source, the company's patient support program. The number of new patient prescriptions includes patients whose treatment was reimbursed and patients who received free medicine under GBT's patient assistance program due to insurance not providing coverage or not having insurance," the company said.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$81.88 /

+2.67 (+3.37%)

04/27/20 Stifel
Global Blood Therapeutics initiated with a Buy at Stifel
03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
03/18/20 Cowen
Global Blood Therapeutics Oxbryta launch slowed, says Cowen
Initiation
Global Blood Therapeutics initiated with a Buy at Stifel » 16:19
04/27/20
04/27
16:19
04/27/20
16:19
GBT

Global Blood Therapeutics

$77.56 /

-2.67 (-3.33%)

, NVS

Novartis

$89.70 /

+0.6 (+0.67%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett initiated coverage of Global Blood Therapeutics (GBT) with a Buy rating and $112 price target, stating that he sees the company becoming a strong leader in the Sickle Cell Disease, or SCD, space. He is optimistic that lead product Oxbryta "can on its own bring the company into profitability," with demand expected to come not only from mild SCD patients, but also severe patients, the analyst tells investors. He also contends that the clinical success of Novartis' (NVS) Adakveo "goes a long way to de-risk the P-selectin mechanism and by extension Global Blood Therapeutics' early stage inclacumab program."

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$77.56 /

-2.67 (-3.33%)

03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
03/18/20 Cowen
Global Blood Therapeutics Oxbryta launch slowed, says Cowen
03/17/20 Piper Sandler
Global Blood's Oxbryta revenue could surpass estimates, says Piper Sandler
NVS Novartis
$89.70 /

+0.6 (+0.67%)

04/23/20 Morgan Stanley
Novartis price target lowered to CHF 91 from CHF 93 at Morgan Stanley
04/17/20 BMO Capital
Regeneron price target raised to $466 from $379 at BMO Capital
03/26/20 Argus
Alcon upgraded to Buy from Hold at Argus
03/11/20 Morgan Stanley
Novartis upgraded to Equal Weight yesterday at Morgan Stanley
Over a month ago
Conference/Events
Global Blood Therapeutics participates in a conference call with Cowen » 10:25
04/20/20
04/20
10:25
04/20/20
10:25
GBT

Global Blood Therapeutics

$72.29 /

+1.63 (+2.31%)

Biotechnology Analyst…

Biotechnology Analyst Baral to hold a group conference call with management on April 20 at 11 am hosted by Cowen.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$72.29 /

+1.63 (+2.31%)

03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
03/18/20 Cowen
Global Blood Therapeutics Oxbryta launch slowed, says Cowen
03/17/20 Piper Sandler
Global Blood's Oxbryta revenue could surpass estimates, says Piper Sandler
Conference/Events
Global Blood Therapeutics participates in a conference call with Cowen » 04:55
04/20/20
04/20
04:55
04/20/20
04:55
GBT

Global Blood Therapeutics

$70.66 /

+3.01 (+4.45%)

Biotechnology Analyst…

Biotechnology Analyst Baral to hold a group conference call with management on April 20 at 11 am hosted by Cowen.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$70.66 /

+3.01 (+4.45%)

03/30/20 Piper Sandler
Global Blood selloff prices in Oxbryta delay, says Piper Sandler
03/18/20 Oppenheimer
Global Blood Therapeutics price target lowered to $88 from $100 at Oppenheimer
03/18/20 Cowen
Global Blood Therapeutics Oxbryta launch slowed, says Cowen
03/17/20 Piper Sandler
Global Blood's Oxbryta revenue could surpass estimates, says Piper Sandler

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.